Latest stories on PPCB
Propanc Biopharma (PPCB) Advances PRP Phase 1b Trial for Solid Tumors
GuruFocus58 · neutralproduct/pr
Propanc Biopharma targets February start for first-in-human cancer study
The Fly61 · neutralproduct/pr
Propanc Biopharma announces new PRP preclinical data
The Fly58 · neutralproduct/pr
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
GlobeNewswire63 · neutralproduct/pr
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
Business Insider63 · neutralproduct/pr
Propanc Biopharma Inc trading halted, news pending
The Fly50 · neutralgeneral
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Business Insider32 · bearishgeneral
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
GlobeNewswire32 · bearishgeneral
Propanc Biopharma announces 1-for-10 reverse stock split
The Fly31 · bearishgeneral
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Business Insider32 · bearishgeneral
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
GlobeNewswire32 · bearishgeneral
Propanc Biopharma announces new preclinical research from PRP programs
The Fly56 · neutralproduct/pr
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
GlobeNewswire63 · neutralproduct/pr
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
StockTitan63 · neutralproduct/pr
Propanc highlights preclinical data for PRP in pancreatic ductal adenocarcinoma
The Fly56 · neutralproduct/pr
Propanc Biopharma files to sell 6.5M shares of common stock for holders
The Fly28 · bearishgeneral
Propanc Biopharma, Inc. GAAP EPS of -$17.62
Business Insider22 · bearishearnings
Propanc Biopharma FY26 EPS ($17.62)
The Fly50 · neutralearnings
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Business Insider50 · neutralgeneral
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
GlobeNewswire50 · neutralgeneral